18 May 2020 - The Ministry of Health and Welfare said it would reassess whether choline alfoscerate, a dementia treatment, was worth receiving the national health insurance benefit.

The Health Insurance Policy Review Committee under the ministry said Friday it would review the drug’s reimbursement.

The ministry cited the reasons for the reevaluation as following: the insurance claims have recently increased significantly; no other country grants reimbursement as the drug is used as a health functional food, and the treatment lacks clinical evidence.

Read Korea Biomedical Review article